Nanocyclix® is Oncodesign's proprietary medicinal chemistry technology that is used in its drug and biomarker discovery programs. The application of the technology in a diversity based chemocentric platform approach has allowed Oncodesign to identify attractive lead compounds that are pursued in a series of internal programs. In addition, the broad know-how obtained on the synthesis and optimization of this type of macrocyclic small molecules allows Oncodesign to propose the application of the technology on partner compounds that require further optimization.
info on Nanocyclix®
Nanokinib is a kinase focused library of proprietary small molecule macrocycles that Oncodesign has created using its Nanocyclix® technology. The current library contains over 5,000 diverse kinase inhibitors that were broadly profiled across the human kinome and in early ADMET (eADMET) models. The compounds typically display low nanomolar potencies against a small number of kinases. Inhibitor leads have been discovered both for established and unexplored kinases. Each compound of the Nanokinib library was individually designed to display good cell penetration and attractive physicochemical properties.
More info on Nanokinib